Tiverton Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tiverton Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$5.89M	Buy	34,763 +2,473	+8%	+$437K	0.2%	109
2019 Q2	$5.92M	Sell	32,290 -5,802	-15%	-$1.01M	0.21%	101
2019 Q1	$7.01M	Buy	38,092 +395	+1%	+$73K	0.3%	83
2018 Q4	$6.25M	Sell	37,697 -13,637	-27%	-$2.36M	0.38%	72
2018 Q3	$9.89M	Hold	51,334	–	–	0.49%	54
2018 Q2	$8.72M	Buy	51,334 +7,222	+16%	+$1.12M	0.44%	60
2018 Q1	$7.19M	Buy	44,112 +113	+0.3%	+$18.5K	0.5%	60
2017 Q4	$6.59M	Sell	43,999 -727	-2%	-$108K	0.41%	68
2017 Q3	$6.8M	Sell	44,726 -6,900	-13%	-$1.04M	0.39%	78
2017 Q2	$6.65M	Hold	51,626	–	–	0.36%	89
2017 Q1	$5.64M	Sell	51,626 -44,498	-46%	-$3.92M	0.29%	111
2016 Q4	$7.08M	Buy	96,124 +44,498	+86%	+$3.62M	0.42%	87
2016 Q3	$4.5M	Sell	51,626 -288,390	-85%	-$27.3M	0.36%	92
2016 Q2	$24.8M	Buy	340,016 +191,406	+129%	+$16.5M	1.04%	32
2016 Q1	$11.8M	Sell	148,610 -13,890	-9%	-$1.26M	0.4%	78
2015 Q4	$20.4M	Sell	162,500 -87,500	-35%	-$10.6M	0.65%	55
2015 Q3	$26M	Hold	250,000	–	–	0.58%	61
2015 Q2	$30.9M	Hold	250,000	–	–	0.61%	59
2015 Q1	$29.5M	Hold	250,000	–	–	0.6%	58
2014 Q4	$29.7M	Hold	250,000	–	–	0.62%	58
2014 Q3	$28.1M	Hold	250,000	–	–	0.64%	59
2014 Q2	$23.7M	Sell	250,000 -250,000	-50%	-$17.5M	0.53%	67
2014 Q1	$35.4M	Hold	500,000	–	–	0.77%	55
2013 Q4	$37.1M	Sell	500,000 -150,000	-23%	-$10.4M	0.82%	55
2013 Q3	$49.3M	Sell	650,000 -150,000	-19%	-$11.9M	1.19%	29
2013 Q2	$64M	Buy	+800,000	New	+$58.9M	1.66%	14

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tiverton Asset Management's VRTX Position: Q3 2019 in Review

Tiverton Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.7% in Q3 2019, buying an estimated $437K and bringing the position to 34,763 shares worth $5.89M. The position accounts for 0.2% of the portfolio, ranked #109.

Tiverton Asset Management first reported a position in VRTX in Q2 2013 and has held it in 26 quarters since. The position peaked at $64M in Q2 2013. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

Tiverton Asset Management held 34,763 shares of Vertex Pharmaceuticals worth $5.89M as of Q3 2019.
Tiverton Asset Management bought 2,473 Vertex Pharmaceuticals shares in Q3 2019, an estimated $437K.
Vertex Pharmaceuticals made up 0.2% of Tiverton Asset Management's portfolio in Q3 2019, its #109 holding.
Tiverton Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
Tiverton Asset Management's Vertex Pharmaceuticals position peaked at $64M in Q2 2013.
708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.